{"id":"W3118507153","doi":"10.1158/1078-0432.ccr-20-3706","title":"Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":196,"is_retracted":false,"has_abstract":true,"ca_institutions":"Trillium Therapeutics (Canada); Spinal Cord Injury BC; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"National Institutes of Health","keywords":"Medicine; Refractory (planetary science); Chills; Rituximab; Lymphoma; Internal medicine; Clinical endpoint; Gastroenterology; Adverse effect; Nivolumab; Phases of clinical research; Surgery; Chemotherapy; Cancer; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001299312,0.0001129114,0.0004327564,0.00007556784,0.0001608485,0.00001081176,0.0003260419,0.0002124295,0.0006695032],"category_scores_gemma":[0.0009731129,0.00006062134,0.0000766837,0.000619599,0.0005106606,0.00006790177,0.0002794426,0.0008226318,0.00002263006],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008221669,"about_ca_system_score_gemma":0.0005028523,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001696195,"about_ca_topic_score_gemma":0.0005478845,"domain_scores_codex":[0.9965385,0.001883251,0.000656377,0.0003824621,0.0001853461,0.0003541226],"domain_scores_gemma":[0.9979167,0.0007711736,0.0001667674,0.0006083321,0.0005141221,0.00002290125],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.005775746,0.01569373,0.9528498,0.00004576294,0.0002304191,0.00001949503,0.0008283821,0.000005087811,0.0135995,0.00005705744,0.002693882,0.008201145],"study_design_scores_gemma":[0.01997417,0.004520383,0.9499443,0.0001937503,0.00003165395,0.00000272243,0.001284037,0.000002566522,0.01884227,0.00003973887,0.005041684,0.0001226805],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.997073,0.001611822,7.506932e-7,0.000257612,0.0003284854,0.0005983298,0.00001558892,0.000009164964,0.0001052774],"genre_scores_gemma":[0.9977515,0.0001382958,0.000006687688,0.00005506681,0.00001729575,0.00008698756,0.00001667901,0.00001254769,0.001914918],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01419842,"threshold_uncertainty_score":0.733059,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.159802523185442,"score_gpt":0.4642106808345872,"score_spread":0.3044081576491452,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}